Dual antiplatelet therapy (DAPT), the combination of aspirin (ASA), and a P2Y12 inhibitor, protects against stent thrombosis new atherothrombotic events after implantation or an acute coronary syndrome, but exposes patients to increased risk bleeding. In most current practices, inhibitor is stopped at 6 12 months ASA continued indefinitely. The advent safer stents, with less thrombosis, has cha...

BACKGROUND  The question as to whether triple antiplatelet therapy is superior to dual antiplatelet therapy for patients with acute myocardial infarction (AMI) and renal dysfunction, who undergo percutaneous coronary intervention (PCI), is unresolved. METHODS AND RESULTS  As part of the Korea Acute Myocardial Infarction Registry (KAMIR), 2,288 AMI patients with renal dysfunction (glomerular f...

It has been shown that triple antiplatelet therapy with cilostazol results in better clinical outcomes than dual therapy in patients treated with a first-generation drug-eluting stent (DES); however, it is unclear whether triple antiplatelet therapy has a similar efficacy after the implantation of second-generation DES.In the COACT (Cath Olic medical center percutAneous Coronary in Tervention) ...

In patients on chronic oral anticoagulation (OAC) who are undergoing a percutaneous coronary intervention (PCI), dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) is required. However, combining dual antiplatelet therapy with OAC increases the risk of bleeding. Newer and stronger P2Y12 inhibitors also add more complexity to the regimen, as these antiplatelet agents are currently recomme...

BACKGROUND AND PURPOSE Antiplatelets are recommended for patients with acute noncardioembolic stroke or transient ischemic attack. We compared the safety and efficacy of dual versus mono antiplatelet therapy in patients with acute ischemic stroke or transient ischemic attack. METHODS Completed randomized controlled trials of dual versus mono antiplatelet therapy in patients with acute (≤3 day...

A 64-year-old man has permanent atrial fibrillation and chronic hypertension. He has been treated with atenolol 50 mg daily, lisinopril 10 mg daily, and warfarin for the last 4 years. Otherwise, he is in good shape and employed full-time as a technical director of a large shipbuilding company. At a routine visit about 1 year ago, he complained of chest pain and dyspnea on exertion. An exercise ...

BACKGROUND Emerging studies suggest that early administration of dual antiplatelet therapy may be better than monotherapy for prevention of early recurrent stroke and cardiovascular outcomes in acute ischemic stroke and transient ischemic attack (TIA). We performed a meta-analysis of randomized, controlled trials evaluating dual versus mono antiplatelet therapy for acute noncardioembolic ischem...